MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com

A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Placebo
Drug: RO7020531
First Posted Date
2018-05-21
Last Posted Date
2020-07-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
70
Registration Number
NCT03530917
Locations
🇭🇰

Prince of Wales Hospital, Shatin, New Territories, Hong Kong

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Phase 3
Active, not recruiting
Conditions
Progressive Multiple Sclerosis (PMS)
Interventions
First Posted Date
2018-05-14
Last Posted Date
2024-12-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
927
Registration Number
NCT03523858
Locations
🇺🇸

Cleveland Clinic Mellen Center; U10, Cleveland, Ohio, United States

🇺🇸

University of Cincinnati; Department of Neurology, Cincinnati, Ohio, United States

🇺🇸

Lone Star Neurology of San Antonio, San Antonio, Texas, United States

and more 123 locations

Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

Phase 1
Completed
Conditions
Autism Spectrum Disorder
Interventions
Drug: RO7017773
Other: [11C] Ro15-4513
First Posted Date
2018-04-25
Last Posted Date
2019-09-30
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
6
Registration Number
NCT03507569
Locations
🇬🇧

Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: RO7062931
Drug: Placebo
First Posted Date
2018-04-23
Last Posted Date
2020-08-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
41
Registration Number
NCT03505190
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

🇭🇰

Prince of Wales Hospital, Shatin, New Territories, Hong Kong

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

Phase 3
Terminated
Conditions
Autism Spectrum Disorder
Interventions
Drug: Placebo
Drug: Balovaptan
First Posted Date
2018-04-20
Last Posted Date
2021-10-27
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
322
Registration Number
NCT03504917
Locations
🇺🇸

Woodland Research Northwest, LLC, Rogers, Arkansas, United States

🇺🇸

MCB Clinical Research Centers, Colorado Springs, Colorado, United States

🇺🇸

Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States

and more 48 locations

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Phase 3
Terminated
Conditions
Triple Negative Breast Cancer
Interventions
Drug: Atezolizumab
Drug: Paclitaxel
Drug: Dose-dense Doxorubicin or dose-dense Epirubicin
Drug: Cyclophosphamide
First Posted Date
2018-04-17
Last Posted Date
2024-08-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
2199
Registration Number
NCT03498716
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

🇦🇺

Royal Adelaide Hospital; Cancer Centre, Adelaide, South Australia, Australia

and more 361 locations

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

First Posted Date
2018-04-13
Last Posted Date
2024-06-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
528
Registration Number
NCT03498521
Locations
🇦🇺

Northern Cancer Institute, St Leonards, New South Wales, Australia

🇦🇺

Blacktown Hospital, Blacktown, New South Wales, Australia

🇫🇮

Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland

and more 134 locations

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Phase 3
Completed
Conditions
Early Breast Cancer
Interventions
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Docetaxel
Drug: Paclitaxel
Drug: Pertuzumab IV
Drug: FDC of Pertuzumab and Trastuzumab SC
Drug: Trastuzumab IV
Drug: Trastuzumab SC
Procedure: Surgery
Radiation: Post-operative Radiotherapy
Drug: Hormone Therapy
First Posted Date
2018-04-11
Last Posted Date
2024-06-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
500
Registration Number
NCT03493854
Locations
🇨🇦

The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

🇯🇵

St. Luke's International Hospital, Tokyo, Japan

🇧🇪

Institut Jules Bordet, Anderlecht, Belgium

and more 104 locations

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Phase 3
Terminated
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2018-04-09
Last Posted Date
2020-07-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
149
Registration Number
NCT03491150
Locations
🇺🇸

Anderson Clinical Research, Inc., Redlands, California, United States

🇺🇸

University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States

🇫🇷

Hopital La Grave; Place Lange, Toulouse Cedec, France

and more 63 locations

Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System

Not Applicable
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Device: Accu-Chek® Solo micropump system
Device: mylife™ OmniPod® Insulin Management System
Other: Multiple Daily Injections (MDI) therapy
First Posted Date
2018-03-27
Last Posted Date
2021-08-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
181
Registration Number
NCT03478969
Locations
🇦🇹

Hietzing Hospital, Vienna, Austria

🇩🇪

Diabetes Klinik Bad Mergentheim GmbH, Bad Mergentheim, Germany

🇩🇪

InnoDiab Forschung GmbH, Essen, Germany

and more 18 locations
© Copyright 2025. All Rights Reserved by MedPath